Literature DB >> 8647258

Glucose catabolism in cancer cells: regulation of the Type II hexokinase promoter by glucose and cyclic AMP.

A Rempel1, S P Mathupala, P L Perdersen.   

Abstract

The increased glucose consumption of many tumor cells depends to a large extent on the overexpression of hexokinase Type II. In a previous study we isolated and sequenced the hepatoma Type II hexokinase promoter and showed that it is activated by glucose in the highly glycolytic AS-30D hepatoma cell line under study, but not activated in control hepatocytes [Mathupala, S.P., Rempel, A. and Pedersen, P.L. (1995) J. Biol. Chem. 270, 16918-16925]. Here we report that the promoter of the hexokinase Type II gene is maximally activated by glucose at concentrations above 5 mM. Moreover, the data strongly suggest that glucose can act alone without requirement for metabolism. Also, glucose-mediated promoter activation is markedly potentiated by cAMP. This response may serve as a strategy for cancer cells to maintain the hexokinase transcription rate high to ensure an efficient glucose utilization even under conditions where carbohydrates are limiting.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647258     DOI: 10.1016/0014-5793(96)00399-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  12 in total

Review 1.  Genetic insights into OXPHOS defect and its role in cancer.

Authors:  Dhyan Chandra; Keshav K Singh
Journal:  Biochim Biophys Acta       Date:  2010-11-11

Review 2.  Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy.

Authors:  Saroj P Mathupala; Young H Ko; Peter L Pedersen
Journal:  Semin Cancer Biol       Date:  2008-12-03       Impact factor: 15.707

Review 3.  Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria.

Authors:  S P Mathupala; Y H Ko; P L Pedersen
Journal:  Oncogene       Date:  2006-08-07       Impact factor: 9.867

4.  The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer.

Authors:  Hisataka Ogawa; Hiroaki Nagano; Masamitsu Konno; Hidetoshi Eguchi; Jun Koseki; Koichi Kawamoto; Naohiro Nishida; Hugh Colvin; Akira Tomokuni; Yoshito Tomimaru; Naoki Hama; Hiroshi Wada; Shigeru Marubashi; Shogo Kobayashi; Masaki Mori; Yuichiro Doki; Hideshi Ishii
Journal:  Mol Clin Oncol       Date:  2015-01-22

Review 5.  Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase.

Authors:  S P Mathupala; A Rempel; P L Pedersen
Journal:  J Bioenerg Biomembr       Date:  1997-08       Impact factor: 2.945

Review 6.  Metabolic Strategies for Inhibiting Cancer Development.

Authors:  Philippe Icard; Mauro Loi; Zherui Wu; Antonin Ginguay; Hubert Lincet; Edouard Robin; Antoine Coquerel; Diana Berzan; Ludovic Fournel; Marco Alifano
Journal:  Adv Nutr       Date:  2021-07-30       Impact factor: 8.701

7.  High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation.

Authors:  Charupong Saengboonmee; Wunchana Seubwai; Chawalit Pairojkul; Sopit Wongkham
Journal:  Sci Rep       Date:  2016-01-08       Impact factor: 4.379

8.  Antitumoural activity of a cytotoxic peptide of Lactobacillus casei peptidoglycan and its interaction with mitochondrial-bound hexokinase.

Authors:  Giuseppe A Fichera; Marco Fichera; Giuseppe Milone
Journal:  Anticancer Drugs       Date:  2016-08       Impact factor: 2.248

Review 9.  High glucose: an emerging association between diabetes mellitus and cancer progression.

Authors:  Suangson Supabphol; Wunchana Seubwai; Sopit Wongkham; Charupong Saengboonmee
Journal:  J Mol Med (Berl)       Date:  2021-05-26       Impact factor: 4.599

Review 10.  Nuclear receptors and the Warburg effect in cancer.

Authors:  James L Thorne; Moray J Campbell
Journal:  Int J Cancer       Date:  2014-06-16       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.